Opendata, web and dolomites

REAP SIGNED

Repair of DNA lesions induced by platinum drugs

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 REAP project word cloud

Explore the words cloud of the REAP project. It provides you a very rough idea of what is the project "REAP" about.

genome    multiple    characterization    understand    backgrounds    considerable    techniques    treatment    nonmalignant    cas9    receiving    patient    experimental    drugs    platinum    ambition    regulate    schemes    outcomes    follows    versus    patients    cancer    cytotoxicity    observations    dna    difference    striking    molecular    unbiased    host    data    scientific    knockout    cisplatin    deficient    genetic    tissues    mutated    treat    half    benefit    bulky    functional    novelty    damage    cells    crispr    ddr    gg    vital    insensitive    union    shown    extrapolate    potentially    genes    repair    translational    principles    efficient    performing    multidisciplinary    validation    ner    differential    recognition    validated    oxaliplatin    nucleotide    unrecognized    lesions    unable    excision    experts    screens    unreported    tumor    global    pilot    expressed    commitment    identification    sensitive    differently    inducing    transfer    followed    chemotherapy    resistance    tumors   

Project "REAP" data sheet

The following table provides information about the project.

Coordinator
CEMM - FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZIN GMBH 

Organization address
address: LAZARETTGASSE 14 AKH BT 25.3
city: WIEN
postcode: 1090
website: http://www.oeaw.ac.at/

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Austria [AT]
 Total cost 186˙167 €
 EC max contribution 186˙167 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2018
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2021-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CEMM - FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZIN GMBH AT (WIEN) coordinator 186˙167.00

Map

 Project objective

DNA damage-inducing platinum drugs, such as oxaliplatin and cisplatin, are used to treat about half of all patients receiving chemotherapy. Although potentially very efficient, many patients develop resistance for yet unrecognized reasons. Better understanding of the DNA damage response (DDR) to platinum-DNA lesions is therefore much needed for improving treatment outcomes. By performing DDR-dedicated CRISPR/Cas9 knockout screens, the applicant has shown that some cancer cells deficient in the major repair of bulky DNA lesions, global-genome nucleotide excision repair (GG-NER), are insensitive to oxaliplatin but sensitive to cisplatin. This striking difference remains as of yet unreported, but might explain differential responses of tumors to drugs. The aim of this proposal is to understand why GG-NER is unable to repair oxaliplatin lesions in particular genetic backgrounds. To do so, unbiased identification of genes differently mutated or expressed in oxaliplatin-sensitive versus insensitive cells will be followed by validation and in-depth functional characterization of identified targets. The ambition is to extrapolate experimental observations to translational knowledge. Validated targets will be studied in patient-derived tumor tissues as compared to nonmalignant tissues and related to patients’ treatment responses. Identification of genetic factors that regulate platinum lesions recognition by GG-NER will contribute to the understanding of molecular principles of platinum drugs cytotoxicity and might thus have considerable benefit on current cancer treatment schemes. The novelty of the pilot data, the unique multidisciplinary design of the project, the use of state-of-the-art molecular techniques and a collaboration with multiple European experts will ensure high scientific impact. Both, the applicant and the host will greatly benefit from the vital knowledge transfer. This project follows the European Union's commitment to cancer research.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "REAP" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "REAP" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

Mel.Photo.Protect (2019)

Unraveling the Photoprotecting Mechanism of Melanin - From a Library of Fragments to Simulation of Spectra and Function

Read More  

ReSOLeS (2019)

New Reconfigurable Spectrum Optical Fibre Laser Sources

Read More  

EVOMET (2019)

The rise and fall of metastatic clones under immune attack

Read More